Burundi vs Mexico: Average cost of multi drug-resistant tuberculosis treatment
Burundi
1,051 constant 2022 US$
in 2024
Mexico
1,000 constant 2022 US$
in 2024
Burundi rank
45th
Mexico rank
48th
Average cost of multi drug-resistant tuberculosis treatment over time
- Burundi
- Mexico
How they compare
Burundi currently reports 1,051 constant 2022 US$ against 1,000 constant 2022 US$ in Mexico, a difference of 51 constant 2022 US$.
That makes Burundi's figure about 1.1 times Mexico's.
The two have swapped places 2 times across 7 shared years of data; in 2017 it was Burundi ahead.
Burundi ranks 45th and Mexico ranks 48th of 92 countries.
Burundi has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Burundi | Mexico | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,067 constant 2022 US$ | 1,022 constant 2022 US$ | 1,046 constant 2022 US$ | Burundi |
| 2020s | 1,020 constant 2022 US$ | 986.2 constant 2022 US$ | 33.6 constant 2022 US$ | Burundi |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Burundi or Mexico?
- Burundi, at 1,051 constant 2022 US$ against 1,000 constant 2022 US$ in Mexico as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Burundi and Mexico?
- 51 constant 2022 US$, with Burundi ahead.
- How many years of comparable data are there for Burundi and Mexico?
- 7 years are reported by both, from 2017 to 2024.
- How do Burundi and Mexico rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Burundi ranks 45th and Mexico ranks 48th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.